Methods, systems, and devices are described for fabricating, providing, and using an orogastric tube. The orogastric tube may have, among other things: a proximal end section; a distal end section opposite the proximal end section and having a flexible, resilient curved portion; at least one sump channel extending from the proximal end section along a pre-determined length of the orogastric tube into the distal end section; at least one suction channel extending from the proximal end section along a pre-determined length of the orogastric tube into the distal end section; and optionally at least one balloon channel extending from the proximal end section along a pre-determined length of the orogastric tube to the distal end section. The optional balloon channel is in communication with an expandable balloon in the distal end section; and a main channel encloses a pre-determined length of the sump channel, the suction channel, and, if present, the balloon channel.

The present invention relates to a reflux disease treatment apparatus, comprising two or more movement restriction device segments adapted to form an implantable movement restriction device with an elongated shape that maintains cardia in the correct position. The movement restriction device has proximal and a distal end, wherein the distal end is adapted to stabilize and hold the proximal end. The invention further comprises a control device for controlling the stimulation device to stimulate the cardia sphincter. The distal end can be further adapted to treat obesity, for example by stretching the wall of the stomach or filling out a volume of the stomach.

An intraluminar method of treating obesity of a patient, having a stomach with a food cavity, is disclosed. The method comprises the steps of creating a pouch made of a stomach wall portion of the patient, closing the pouch by sutures, staples or a fixation device, and placing a volume filling device in the pouch before or after closing the pouch, and thus investigating the volume filling device in the pouch such that an outer surface of the volume filling device rests against an outer surface of the stomach wall.

An apparatus for treating obesity in a human or animal mammal patient. The apparatus comprising a first volume filling device segment and a second volume filling device segment. The first and second volume filling device segments are adapted to be assembled into an implantable volume filling device of a controlled size. Each one of the first and second volume filling device segment comprises at least one interconnecting structure. The interconnecting structure of the second volume filling device segment is adapted to be formed fitted, such that the first and second volume filling device segment can be assembled into the volume filling device. The assembled volume filling device is adapted to be at least substantially invaginated by a stomach wall portion of a patient, with the outer surface of the device resting against the stomach wall, such that the volume of the food cavity is reduced in size.

A system for treating a patient comprises a delivery device and injectate. The delivery device comprises an elongate shaft with a distal portion and at least one delivery element positioned on the elongate shaft distal portion. The delivery device is constructed and arranged to deliver the injectate through the at least one delivery element and into tissue to create a therapeutic restriction in the gastrointestinal tract. Methods of creating a therapeutic restriction are also provided.

An volume filling device for treatment of obesity is placed outside the stomach wall of the patient to reduce the inner volume of the stomach, thereby affecting the patient's appetite. By providing the volume filling device outside the stomach wall, contact with stomach acids is avoided, thereby increasing the life of the device.

Methods, systems, and devices are described for fabricating, providing, and using an orogastric tube. The orogastric tube may have, among other things: a proximal end section; a distal end section opposite the proximal end section and having a flexible, resilient curved portion; at least one sump channel extending from the proximal end section along a pre-determined length of the orogastric tube into the distal end section; at least one suction channel extending from the proximal end section along a pre-determined length of the orogastric tube into the distal end section; and optionally at least one balloon channel extending from the proximal end section along a pre-determined length of the orogastric tube to the distal end section. The optional balloon channel is in communication with an expandable balloon in the distal end section; and a main channel encloses a pre-determined length of the sump channel, the suction channel, and, if present, the balloon channel.

An obesity treatment device is provided, the device comprising: at least one operable stretching device implantable in an obese patient and adapted to stretch a portion of the patient's stomach wall and an operation device for operating the stretching device when implanted to stretch the stomach wall portion such that satiety is created.

The invention relates to an intraluminar method of treating a reflux disease in a patient by implanting a device comprising an movement restriction device that, when implanted in a patient, fills a volume in the patient's abdomen that is close to and at least partially above the patient's cardia when the patient is in a standing position. The invention further relates to a method of restoring the location of the cardia in a patient suffering from a reflux disease and to an instrument suitable to use with intraluminar method and/or restoration method. Also disclosed are instruments treating a patient suffering hiatal hernia and providing a movement restriction device to be invaginated in the stomach fundus wall.

The present invention teaches a method and apparatus for physiological modulation, including neural, gastrointestinal, renal, respiratory, and other modulation, for the purposes of treating several disorders, including obesity, depression, epilepsy, diabetes, hypertension, asthma, and other disorders. This includes implanted, percutaneous, hybrid implanted and nonimplanted, nonimplanted, noninvasive neural and neuromuscular modulators, used to deliver autonomic vector modulation to deliver optimal therapy via coordinated multi-nodal modulation at least one of the afferent and efferent neurons of the sympathetic and parasympathetic nervous systems and other nervous system pathways.